HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: Site selection and inhibition in cell culture

Nucleic Acids Research

Volumn 28, Issue 21, 2000, Pages 4059-4067

  Bramlage, Birgit ^a   Luzi, Ettore ^a   Eckstein, Fritz ^a,b  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MESSENGER RNA; PHOSPHOROTHIOIC ACID; PLASMID DNA; RIBONUCLEASE; RIBOZYME; RNA; VIRUS RNA;

ARTICLE; CELL CULTURE; CODON; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; REPORTER GENE; RNA CLEAVAGE; RNA SEQUENCE; RNA TRANSCRIPTION;

EID: 0034327421     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/28.21.4059     Document Type: Article

References (62)

1. The structure, function and application of the hammerhead ribozyme
2. Designing ribozymes for the inhibition of gene expression
3. The therapeutic potential of ribozymes
4. Ribozymes and the anti-gene therapy: How a catalytic RNA can be used to inhibit gene function
5. Efficient long-term coexpression of a hammerhead ribozyme targeted to the U5 region of HIV-1 LTR by linkage to the multidrug-resistance gene
6. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular concentration
7. Preclinical characterization of an anti-tat ribozyme for therapeutic application
8. Inhibition of HIV-1 replication by an anti-tat hammerhead ribozyme
9. Design and anti-HIV-1 activity of hammerhead and hairpin ribozymes containing a stable loop
10. tRNA(Val)-heterodimeric maxizymes with high potential as gene-inactivating agents: Simultaneous cleavage at two sites in HIV-1 tat mRNA in cultured cells
11. + T cells in vitro
12. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes
13. Structural Biology of HIV
14. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter
15. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes
16. Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1
17. High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates
18. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
19. Selecting effective antisense reagents on combinatorial oligonucleotide arrays
20. The effect of structure in a long target RNA on ribozyme cleavage efficiency
21. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity
22. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
23. Probing accessible sites for ribozymes on human acetylcholinesterase RNA
24. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts
25. RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts
26. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability
27. Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: Ribozyme-mediated reduction of the murine DNA methyltransferase
28. Ribozyme-mediated repair of sickle β-globin mRNAs in erythrocyte precursors
29. Cleavage of highly structured viral RNA molecules by combinatorial libraries of hairpin ribozymes
30. Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus
31. Target site selection for an RNA-cleaving catalytic DNA
32. Vectors for efficient expression in mammalian fibroblastoid, myeloid and lymphoid cells via tranfection or infection
33. Elevated levels of mRNA can account for the transactivation of human immunodeficiency virus
34. AUA-cleaving hammerhead ribozymes: Attempted selection for improved cleavage
35. Hammerhead ribozymes: Importance of stem-loop II for activity
36. In vitro selection of a purine nucleotide-specific hammerhead-like ribozyme
37. Nuclease resistant ribozymes with high catalytic activity
38. Chemical modification of hammerhead ribozymes
39. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA
40. Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo
41. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake
42. + cells to the alkylating antineoplastic drug
43. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA
44. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture
45. 2 receptor ribozyme inhibits quinpirole-induced stereotypy in rats
46. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes
47. The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells
48. A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo
49. A nuclease-resistant protein kinase Cα ribozyme blocks glioma cell growth
50. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint
51. Functional characterization of a U5 ribozyme: Intracellular suppression of human immunodeficiency virus type 1 expression
52. Use of adenoviral VAI small RNA as carrier for cytoplasmic delivery of ribozymes
53. Ribozyme targeting of HIV-1 LTR
54. Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model
55. Functional sites in the 5' region of human immunodeficiency virus type 1 RNA form defined structural domains
56. Determining the influence of structure on hybridization using oligonucleotide arrays
57. Hybridization prediction gets to first base
58. Tat trans-activates the human immunodeficiency virus through a nascent RNA target
59. HIV-1 tat protein increases transcriptional initiation and stabilizes elongation
60. Identification and partial purification of human double strand RNase activity